OR4C3

Across TCGA pan-cancer cohorts, OR4C3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR4C3 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher OR4C3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR4C3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

THCA, ESCA, and SARC are the cancer types where OR4C3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.049	0.841	<.001	24	view →
ESCA	OS	Median	II,III,IV	0.206	0.686	.011	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
UCEC	DFS	Median	All	1.000	0.628	.025	6	view →
HNSC	OS	Median	All	0.151	0.685	.007	3	view →
SKCM	OS	Median	All	0.962	0.867	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR4C3–THCA (DFS)

Open the THCA breakdown →